TELO (Telomir Pharmaceuticals) Gross Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Telomir Pharmaceuticals's Gross Profit for the three months ended in Dec. 2024 was $0.00 Mil. Telomir Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Telomir Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Telomir Pharmaceuticals's Gross Margin % or its related term are showing as below:

TELO's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 59.89
* Ranked among companies with meaningful Gross Margin % only.

Telomir Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Telomir Pharmaceuticals was 0.00% per year.

Telomir Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Telomir Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Gross Margin % Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Gross Margin %

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Telomir Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Telomir Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telomir Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Gross Margin % falls into.

Save Embed

;

Save Embed

;

Telomir Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Telomir Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )	=	Gross Profit (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

Telomir Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )	=	Gross Profit (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Telomir Pharmaceuticals (NAS:TELO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Telomir Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Telomir Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 South East, 2nd Street, Suite 200, No.1009, Miami, FL, USA, 33131

Website

https://www.telomirpharma.com

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.